{"id":2815,"date":"2018-07-25T18:08:18","date_gmt":"2018-07-25T12:38:18","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2815"},"modified":"2021-07-24T12:57:01","modified_gmt":"2021-07-24T07:27:01","slug":"snippet-endometriosis","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/snippet-endometriosis","title":{"rendered":"Snippet : Endometriosis"},"content":{"rendered":"<p>The FDA has approved AbbVie&#8217;s Gonadotropin-Releasing Hormone (GnRH) antagonist\u00a0Elagolix on Tuesday. FDA has given green light to the first oral treatment for endometriosis pain. The drug is branded as Orilissa, and is expected to be available in U.S. pharmacies in August. It will carry a list price of about $850 per month, or just over $10,100 per year. Abbott paid $75 million and agreed to pay $500 million in development process. The drug cost watchdog, also stated \u00a0in\u00a0the June report\u00a0that the drug can still tax the healthcare system based on the number of women affected with <a href=\"https:\/\/www.delveinsight.com\/report-store\/endometriosis-market\">endometriosis<\/a>. Orilissa is one of the new drugs to hit the market for endometriosis pain. There are two other drugs in late-stages, as well as 11 drugs in the mid-stage pipeline.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA has approved AbbVie&#8217;s Gonadotropin-Releasing Hormone (GnRH) antagonist\u00a0Elagolix on Tuesday. FDA has given green light to the first oral treatment for endometriosis pain. The drug is branded as Orilissa, and is expected to be available in U.S. pharmacies in August. It will carry a list price of about $850 per month, or just over [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2817,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[2405,17632,17633],"industry":[17225],"therapeutic_areas":[17411],"class_list":["post-2815","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-abbott","tag-endometriosis-pain","tag-orilissa","industry-pharmaceutical","therapeutic_areas-womens-health"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Snippet : Endometriosis - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"The FDA has approved AbbVie&#039;s (GnRH) antagonist\u00a0Elagolix on Tuesday. FDA has given green light irst oral treatment for endometriosis pain...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/snippet-endometriosis\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Snippet : Endometriosis - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"The FDA has approved AbbVie&#039;s (GnRH) antagonist\u00a0Elagolix on Tuesday. FDA has given green light irst oral treatment for endometriosis pain...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/snippet-endometriosis\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-07-25T12:38:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/07\/09024417\/immunity.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1152\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Snippet : Endometriosis - DelveInsight Business Research","description":"The FDA has approved AbbVie's (GnRH) antagonist\u00a0Elagolix on Tuesday. FDA has given green light irst oral treatment for endometriosis pain...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/snippet-endometriosis","og_locale":"en_US","og_type":"article","og_title":"Snippet : Endometriosis - DelveInsight Business Research","og_description":"The FDA has approved AbbVie's (GnRH) antagonist\u00a0Elagolix on Tuesday. FDA has given green light irst oral treatment for endometriosis pain...","og_url":"https:\/\/www.delveinsight.com\/blog\/snippet-endometriosis","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-07-25T12:38:18+00:00","article_modified_time":"2021-07-24T07:27:01+00:00","og_image":[{"width":1536,"height":1152,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/07\/09024417\/immunity.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/snippet-endometriosis","url":"https:\/\/www.delveinsight.com\/blog\/snippet-endometriosis","name":"Snippet : Endometriosis - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/snippet-endometriosis#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/snippet-endometriosis#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/07\/09024417\/immunity.jpg","datePublished":"2018-07-25T12:38:18+00:00","dateModified":"2021-07-24T07:27:01+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The FDA has approved AbbVie's (GnRH) antagonist\u00a0Elagolix on Tuesday. FDA has given green light irst oral treatment for endometriosis pain...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/snippet-endometriosis"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/snippet-endometriosis#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/07\/09024417\/immunity.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/07\/09024417\/immunity.jpg","width":1536,"height":1152,"caption":"endometriosis"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/07\/09024417\/immunity-300x225.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Abbott<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Endometriosis Pain<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Orilissa<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Abbott<\/span>","<span class=\"advgb-post-tax-term\">Endometriosis Pain<\/span>","<span class=\"advgb-post-tax-term\">Orilissa<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jul 25, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jul 25, 2018 6:08 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2815","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2815"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2815\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2817"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2815"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2815"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2815"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2815"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2815"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}